• Je něco špatně v tomto záznamu ?

The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms

I. Borbath, R. Garcia-Carbonero, D. Bikmukhametov, P. Jimenez-Fonseca, A. Castaño, J. Barkmanova, E. Sedlackova, A. Kollár, E. Christ, G. Kaltsas, B. Kos-Kudla, S. Maasberg, C. Verslype, UF. Pape

. 2022 ; 168 (-) : 80-90. [pub] 20220423

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018156

BACKGROUND: Neuroendocrine neoplasms (NENs) are rare tumours with variable clinical behaviour. Their natural history is ideally best approached in large, multicentre and multinational registries with long-term patients' follow-up. The European Neuroendocrine Tumour Society registry aims to obtain information regarding NEN outcomes and prognostic factors in a European frame. PATIENTS AND METHODS: We collected data from 7 national NEN registries (Belgium, Czech Republic, Germany, Greece, Poland, Spain, Switzerland), representing 10,102 patients. Anonymised/pseudonymised data were collected in a secured server. Descriptive statistical methods were applied, as well as Kaplan-Meier survival curves and multivariable analyses for prognostic factors of overall survival (OS). RESULTS: median age of the study population was 60 years (range: 18-102), 48% were female. Common primary tumour sites were pancreas (27%) and small intestine (21%). Stage 4 disease was found in 47% of patients, while 26/10/16% had stage 1/2/3 disease, respectively. Grading (n = 6952) was G1/2/3 in 48/37/15% of the patients, respectively. Surgery was the main treatment, provided to 71% of patients, followed by somatostatin analogues (32%), chemotherapy (20%), Peptide receptor Radionuclide Therapy (PRRT) (9%) and targeted therapies (8%). OS at 5 years was 74%, influenced by grade, stage and tissue of origin in multivariate analysis. A Ki67 cut-off value set at 55% within the G3 group allowed to separate 2 groups with a meaningful different OS. CONCLUSION: We report the first analysis of the European Neuroendocrine Tumour Society registry, comprising 10,102 patients with NEN from 7 European countries. This large cohort study describes prognostic factors for the survival of NENs throughout Europe, including primary tumour site, grade, stage and treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018156
003      
CZ-PrNML
005      
20220804134605.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejca.2022.03.007 $2 doi
035    __
$a (PubMed)35472579
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Borbath, Ivan $u Hepato-gastroenterology Unit, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium. Electronic address: ivan.borbath@saintluc.uclouvain.be
245    14
$a The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms / $c I. Borbath, R. Garcia-Carbonero, D. Bikmukhametov, P. Jimenez-Fonseca, A. Castaño, J. Barkmanova, E. Sedlackova, A. Kollár, E. Christ, G. Kaltsas, B. Kos-Kudla, S. Maasberg, C. Verslype, UF. Pape
520    9_
$a BACKGROUND: Neuroendocrine neoplasms (NENs) are rare tumours with variable clinical behaviour. Their natural history is ideally best approached in large, multicentre and multinational registries with long-term patients' follow-up. The European Neuroendocrine Tumour Society registry aims to obtain information regarding NEN outcomes and prognostic factors in a European frame. PATIENTS AND METHODS: We collected data from 7 national NEN registries (Belgium, Czech Republic, Germany, Greece, Poland, Spain, Switzerland), representing 10,102 patients. Anonymised/pseudonymised data were collected in a secured server. Descriptive statistical methods were applied, as well as Kaplan-Meier survival curves and multivariable analyses for prognostic factors of overall survival (OS). RESULTS: median age of the study population was 60 years (range: 18-102), 48% were female. Common primary tumour sites were pancreas (27%) and small intestine (21%). Stage 4 disease was found in 47% of patients, while 26/10/16% had stage 1/2/3 disease, respectively. Grading (n = 6952) was G1/2/3 in 48/37/15% of the patients, respectively. Surgery was the main treatment, provided to 71% of patients, followed by somatostatin analogues (32%), chemotherapy (20%), Peptide receptor Radionuclide Therapy (PRRT) (9%) and targeted therapies (8%). OS at 5 years was 74%, influenced by grade, stage and tissue of origin in multivariate analysis. A Ki67 cut-off value set at 55% within the G3 group allowed to separate 2 groups with a meaningful different OS. CONCLUSION: We report the first analysis of the European Neuroendocrine Tumour Society registry, comprising 10,102 patients with NEN from 7 European countries. This large cohort study describes prognostic factors for the survival of NENs throughout Europe, including primary tumour site, grade, stage and treatment.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kohortové studie $7 D015331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a neuroendokrinní nádory $x patologie $7 D018358
650    12
$a nádory slinivky břišní $x patologie $7 D010190
650    _2
$a prognóza $7 D011379
650    12
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a somatostatin $7 D013004
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Garcia-Carbonero, Rocio $u Oncology Department, Hospital Universitario 12 de Octubre, IIS Imas12, UCM, CNIO, CIBERONC, Madrid, Spain. Electronic address: rgcarbonero@gmail.com
700    1_
$a Bikmukhametov, Damir $u Charité University Hospital Berlin, Gastroenterology Department, Berlin, Germany. Electronic address: damirbikm@gmail.com
700    1_
$a Jimenez-Fonseca, Paula $u Hospital Universitario Central de Asturias, Medical Oncology, Oviedo, Asturias, Spain. Electronic address: palucaji@hotmail.com
700    1_
$a Castaño, Angel $u Hospital Universitario de Fuenlabrada, Pathology Unit, Madrid, Spain. Electronic address: angel.castano@salud.madrid.org
700    1_
$a Barkmanova, Jaroslava $u Charles University, Oncological Clinic, General Faculty Hospital and 1.st Medical Faculty, Praha, Czech Republic. Electronic address: jaroslava.barkmanova@vfn.cz
700    1_
$a Sedlackova, Eva $u Charles University, Oncological Clinic, General Faculty Hospital and 1.st Medical Faculty, Praha, Czech Republic. Electronic address: eva.sedlackova@vfn.cz
700    1_
$a Kollár, Attila $u Department of Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland. Electronic address: attila.kollar@insel.ch
700    1_
$a Christ, Emanuel $u Universitätsspital Basel, Endocrinology, Diabetology and Metabolism, Basel, Switzerland. Electronic address: emanuel.christ@usb.ch
700    1_
$a Kaltsas, Gregory $u National and Kapodistrian University of Athens, Department of General Medicine and Endocrinology, Athens, Attica, Greece. Electronic address: gregory.kaltsas@gmail.com
700    1_
$a Kos-Kudla, Beata $u Medical University of Silesia, Department of Pathophysiology and Endocrinology, Katowice, Slaskie, Poland. Electronic address: beatakos@ka.onet.pl
700    1_
$a Maasberg, Sebastian $u Asklepios Kliniken Hamburg, Department of Internal Medicine and Gastroenterology, Hamburg, Germany. Electronic address: s.maasberg@asklepios.com
700    1_
$a Verslype, Chris $u Katholieke Universiteit Leuven, UZ Leuven, Digestive Oncology - Hepatology, Leuven, Belgium. Electronic address: chris.verslype@uzleuven.be
700    1_
$a Pape, Ulrich-Frank $u Asklepios Kliniken Hamburg, Department of Internal Medicine and Gastroenterology, Hamburg, Germany. Electronic address: ul.pape@asklepios.com
773    0_
$w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 168, č. - (2022), s. 80-90
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35472579 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134559 $b ABA008
999    __
$a ok $b bmc $g 1821971 $s 1169399
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 168 $c - $d 80-90 $e 20220423 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
LZP    __
$a Pubmed-20220720
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace